Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Prices of many...

    Prices of many essential drugs to rise up to 2.29 percent post-GST

    Written by Ruby Khatun Khatun Published On 2017-06-14T11:44:23+05:30  |  Updated On 14 Jun 2017 11:44 AM IST
    Prices of many essential drugs to rise up to 2.29 percent post-GST

    New Delhi: Prices of a majority of essential drugs will increase by up to 2.29 per cent when the Goods and Services Tax regime kicks in from next month. The government has fixed GST rate of 12 per cent on most of the essential drugs as against the current tax incidence of around 9 per cent.


    However, some select medicines such as insulin will see a reduction in prices with the government revising GST rate downwards to 5 per cent from 12 per cent proposed earlier. The National List of Essential Medicines includes the likes of Heparin, Warfarin, Diltiazem, Diazepam, Ibuprofen, Propranolol and Imatinib.


    Drug price regulator National Pharmaceutical Pricing Authority (NPPA) has already notified that the revised ceiling prices of scheduled drugs, where excise duty is levied on MRP, will be calculated by applying a factor of 0.95905 to the existing ceiling price. This will be exclusive of applicable GST rates.


    Read Also: How to calculate Pharma Prices with GST: NPPA issues notification


    On the other hand, those scheduled formulations which are exempted from excise duty, their existing notified ceiling price would also be the new ceiling price, exclusive of GST rates, (NPPA) added.


    In the case of non-scheduled formulations, NPPA has said that companies would have no option but to absorb the net increase if prices go up beyond the permissible limit of 10 per cent of MRP due to increase in tax incidence on the GST implementation.


    The regulator is, however, confident that the pharma industry would be in a position to adopt the new tax system without much teething troubles.


    "I am confident that GST implementation will be by and large smooth and will not cause any major disruption in the availability of drugs in the country," NPPA Chairman Bhupendra Singh told PTI.


    In the case of those medicines such as insulin, on which the GST rate has been revised downward to 5 per cent from 12 per cent proposed earlier, companies will be required to reduce the maximum retail price.


    NPPA said in the case of savings due to a lower rate of tax, the benefit may be passed on to the consumers as per the anti-profiteering clause in the GST rules.

    Bhupendra SinghDiazepamDiltiazemessential drugsessential medicinesGoods and Services TaxGSTHeparinibuprofenImatinibNational List of Essential MedicinesNational Pharmaceutical Pricing AuthorityNPPAPropranololwarfarin
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok